Developer docs
API playgroundTry for free, no card

Search company profiles

Phase Scientific

Full company profile

uuid0000hfe

Namestring
Phase Scientific
Legal namestring
PHASE Scientific International Limited
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Phase Scientific is a privately held biotechnology company founded in 2015 as a spin-out from UCLA, headquartered at Hong Kong Science Park with cross-border operations spanning Southern California and Shenzhen's Greater Bay Area. The company has built its business around PHASIFY™, a proprietary urine concentration technology that captures biomarkers at over 10x the sensitivity of industry gold standards, enabling non-invasive sample collection for diagnostic applications spanning cancer early screening, women's health, respiratory infections, gastrointestinal disease, and sexual health. The technology platform underpins a portfolio of over 30 commercialized diagnostic products, including the INDICAID® rapid antigen test line (originally COVID-focused), PhaseLab™ HPV urine detection for cervical cancer screening (demonstrating 93.4% sensitivity for CIN2+ lesions and over 97% concordance with Roche Cobas 4800 for HPV 16/18 detection), and FebriDx®, a rapid point-of-care test differentiating bacterial from non-bacterial respiratory infections.

The company monetizes through multiple revenue streams: direct sales of diagnostic test products (over 100 million test products delivered globally to date across 30+ countries), laboratory testing services through wholly-owned subsidiaries PhaseLab (相达医学) and Onco Medical Laboratory (安球医学化验所) which have collectively conducted over 8 million tests, and channel partnerships. Phase Scientific operates as the exclusive US distributor for FebriDx under a $317 million, 6-year distribution agreement with Lumos Diagnostics, with milestone pre-payments totaling US$7.5 million already paid. Following FDA 510(k) clearance and a March 2026 CLIA waiver, the company has activated commercial infrastructure to deploy FebriDx across over 300,000 US Certificate of Waiver facilities, supported by a CMS reimbursement rate of $41.38 per test. The customer base spans urgent care centers, retail health clinics, hospital systems, and public health screening programs, with go-to-market executed through direct enterprise field sales, clinical research partnerships (notably with Beijing University Shenzhen Hospital on a 17,000-women cervical cancer screening study), and regional distribution agreements.

Short descriptiontext

Phase Scientific is a Hong Kong-headquartered diagnostics company (UCLA spin-out, founded 2015) that has commercialized PHASIFY™, a proprietary urine concentration technology enabling non-invasive biomarker-based testing for cancer screening, women's health, and infectious disease detection across 30+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHong Kong, Hong Kong SAR China
HQ citystring
Hong Kong
HQ countrystring
Hong Kong SAR China
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
urine diagnostics, liquid biopsy tests, rapid antigen tests, cervical cancer screening, point-of-care diagnostics
Industry5 codes
PRIMARYHLAHAAAG
Urinalysis & Routine Screening Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories
NAICS code4 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
In Vitro Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Diagnostic Test Products
TypeHardware Sales
Description

Sale of over 30 innovative diagnostic products across respiratory, gastrointestinal, women's health, sexual health, pediatric health, and oncology. Over 100 million test products delivered globally to date.

incubees.com
2Laboratory Testing Services
TypeProfessional Services
Description

Over 8 million laboratory tests conducted, generating revenue from laboratory service fees.

seekingalpha.com
3Distribution Agreement Revenue
TypeTransaction Fee
Description

Revenue from distribution agreements including milestone pre-payments and product order payments. Total pre-payments from Phase Scientific to Lumos Diagnostics reached US$7.5 million under the FebriDx distribution agreement.

finance.yahoo.com
4FebriDx US Distribution
TypeOne Time License
Description

Commercial deployment of FebriDx point-of-care test across US healthcare settings following FDA CLIA waiver, with reimbursement secured at $41.38 per test from CMS.

clpmag.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others
Pricing details1 tier
1FebriDx test reimbursement
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CMS reimbursement secured at $41.38 per test following FDA CLIA waiver

clpmag.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Phase Scientific develops and commercializes proprietary urine-based diagnostic tests built on its PHASIFY™ urine concentration technology platform, which captures biomarker detection sensitivity over 10x the industry gold standard. The company sells a portfolio of 30+ diagnostic products — including the INDICAID® rapid antigen tests, PhaseLab™ HPV Urine Detection for cervical cancer screening, and the FDA-cleared FebriDx® point-of-care respiratory infection test — and provides clinical laboratory testing services through its PhaseLab and Onco Medical Laboratory subsidiaries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 93.4% sensitivity for CIN2+ lesions in cervical cancer screening using urine HPV testing
+2 more records
Product overview1 text field

Phase Scientific is a biotechnology company that has developed PHASIFY™ as its core proprietary urine concentration technology platform, which captures biomarker detection sensitivity over 10x the industry gold standard. The company offers a portfolio of diagnostic products including INDICAID rapid tests, PhaseLab™ HPV urine detection for cervical cancer screening, and FebriDx® for point-of-care respiratory infection differentiation. The PHASIFY technology platform serves as the foundation enabling multiple product lines spanning cancer early screening, women's health, and infectious disease diagnostics, all based on non-invasive urine sample collection.

Product and service6 records
1PHASIFY™
CategoryCore technology platform
Description

Proprietary urine concentration technology platform that captures biomarker detection sensitivity at over 10 times the industry gold standard, enabling non-invasive early disease detection through liquid biopsy diagnostics. Forms the foundational IP underlying the company's diagnostic products.

2INDICAID® (妥析)
CategoryRapid antigen diagnostic product brand
Description

Brand name under which Phase Scientific offers point-of-care diagnostic products including rapid antigen tests, distributed across multiple countries for infectious disease detection.

3PhaseLab™ HPV Urine Detection
CategoryDiagnostic product - Women's health
Description

Next-generation urine-based HPV DNA detection system for cervical cancer screening; in clinical studies demonstrated over 97% concordance with standard physician-collected samples for HPV 16/18 detection and 93.4% sensitivity for CIN2+ lesions.

4FebriDx®
CategoryDiagnostic product - Respiratory infectious disease
Description

Rapid point-of-care test that differentiates bacterial from non-bacterial respiratory infections; received FDA 510(k) clearance and CLIA waiver, enabling use across over 300,000 US healthcare settings including urgent care centers and retail health clinics.

5PhaseLab (相达医学)
CategoryLaboratory testing services
Description

Laboratory testing services brand offering clinical diagnostic testing services using Phase Scientific's proprietary technologies; over 8 million laboratory tests conducted to date.

6Onco Medical Laboratory (安球医学化验所)
CategoryLaboratory testing services - Oncology
Description

Oncology-focused medical laboratory providing diagnostic testing services related to cancer screening and detection.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Shenzhen Media Public Welfare Foundation
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-03-05
Description

Charitable partnership for cervical cancer screening公益 program targeting 17,000 women in Guang'an region. Donation directed through 'Shenxin Public Welfare Fund' for grassroots female health screening initiatives using Phase Scientific's urine HPV testing technology.

phasescientific.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive US distribution partnership for FebriDx point-of-care test with a $317 million, 6-year distribution agreement. Phase Scientific received milestone pre-payments totaling $7.5 million following FDA CLIA waiver, with commercial infrastructure built out for broad deployment.

3Beijing University Shenzhen Hospital
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical research partner for urine HPV cervical cancer screening studies involving 17,000 women. Published clinical validation data showing 93.4% sensitivity for CIN2+ lesions and over 97% consistency with standard testing. Partner for SCOCCAPS study on cervical cancer prevention innovation model.

phasescientific.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1GRAIL
TypeEmerging player
Description

Multi-cancer early detection company developing Galleri blood-based screening test. Represents the strategic archetype Phase Scientific aims to compete with using urine-based PHASIFY technology, though GRAIL is much further along in clinical validation and commercialization.

TypeBroad incumbent
Description

Global diagnostics incumbent whose Cobas 4800 HPV test is the gold standard that PhaseLab HPV Urine Detection demonstrated 97% concordance with. Operates broadly across IVD, molecular diagnostics, and women's health with significantly larger scale and clinical evidence base.

TypeDirect peer
Description

Market leader in molecular point-of-care testing with GeneXpert systems deployed across US urgent care and hospital settings. Competes with FebriDx in respiratory infection differentiation and represents the dominant POCT benchmark Phase Scientific must displace at Certificate of Waiver facilities.

TypeDirect peer
Description

Leading women's health diagnostics company with the Aptima HPV testing franchise that competes directly with PhaseLab's urine-based HPV detection. Also operates in molecular diagnostics, cervical cancer screening, and infectious disease rapid testing — overlapping multiple Phase Scientific verticals.

TypeEmerging player
Description

Commercial-stage cancer screening company behind Cologuard (CRC) and Oncotype DX. Represents the gold standard business model for non-invasive cancer screening that Phase Scientific's PHASIFY-based liquid biopsy aspirations aim to replicate in urine.

TypeDirect peer
Description

Developer of FebriDx — the rapid point-of-care bacterial vs viral infection test for which Phase Scientific holds exclusive US distribution rights under a $317M, 6-year agreement. Direct product/partner overlap makes Lumos both commercial partner and closest functional peer.

7Sansure Biotech
TypeRegional player
Description

China-based molecular diagnostics company where Phase Scientific's new CSO previously served as CTO. Competes in IVD reagents, infectious disease molecular testing, and cancer diagnostics across Greater China — the most direct regional comparison given overlapping leadership pedigree and product overlap.

TypeRegional player
Description

China-based oncology diagnostics company specializing in next-generation sequencing for cancer therapy selection and minimal residual disease (MRD) testing. Directly comparable to Onco Medical Laboratory in targeting Chinese oncology diagnostics market with molecular approaches.

TypeDirect peer
Description

Specialized rapid diagnostics company with Sofia and Triage product lines for respiratory and infectious disease testing. Competes with both FebriDx in point-of-care respiratory infection differentiation and INDICAID rapid antigen tests, with similar US CLIA-waived distribution channels.

10Abbott Diagnostics
TypeBroad incumbent
Description

Global diagnostics incumbent where Phase Scientific's CSO previously served 18 years. Competes across rapid diagnostics, core laboratory, molecular, and point-of-care testing. Phase Scientific's positioning as a urine-based diagnostics innovator is partly built against Abbott's installed testing infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phase Scientific

In Vitro Diagnosticsphasescientific.com

Phase Scientific is a Hong Kong-headquartered diagnostics company (UCLA spin-out, founded 2015) that has commercialized PHASIFY™, a proprietary urine concentration technology enabling non-invasive biomarker-based testing for cancer screening, women's health, and infectious disease detection across 30+ countries.

What Phase Scientific does

Phase Scientific is a privately held biotechnology company founded in 2015 as a spin-out from UCLA, headquartered at Hong Kong Science Park with cross-border operations spanning Southern California and Shenzhen's Greater Bay Area. The company has built its business around PHASIFY™, a proprietary urine concentration technology that captures biomarkers at over 10x the sensitivity of industry gold standards, enabling non-invasive sample collection for diagnostic applications spanning cancer early screening, women's health, respiratory infections, gastrointestinal disease, and sexual health. The technology platform underpins a portfolio of over 30 commercialized diagnostic products, including the INDICAID® rapid antigen test line (originally COVID-focused), PhaseLab™ HPV urine detection for cervical cancer screening (demonstrating 93.4% sensitivity for CIN2+ lesions and over 97% concordance with Roche Cobas 4800 for HPV 16/18 detection), and FebriDx®, a rapid point-of-care test differentiating bacterial from non-bacterial respiratory infections.

The company monetizes through multiple revenue streams: direct sales of diagnostic test products (over 100 million test products delivered globally to date across 30+ countries), laboratory testing services through wholly-owned subsidiaries PhaseLab (相达医学) and Onco Medical Laboratory (安球医学化验所) which have collectively conducted over 8 million tests, and channel partnerships. Phase Scientific operates as the exclusive US distributor for FebriDx under a $317 million, 6-year distribution agreement with Lumos Diagnostics, with milestone pre-payments totaling US$7.5 million already paid. Following FDA 510(k) clearance and a March 2026 CLIA waiver, the company has activated commercial infrastructure to deploy FebriDx across over 300,000 US Certificate of Waiver facilities, supported by a CMS reimbursement rate of $41.38 per test. The customer base spans urgent care centers, retail health clinics, hospital systems, and public health screening programs, with go-to-market executed through direct enterprise field sales, clinical research partnerships (notably with Beijing University Shenzhen Hospital on a 17,000-women cervical cancer screening study), and regional distribution agreements.

Phase Scientific firmographics

Firmographics
Name
Phase Scientific
Legal name
PHASE Scientific International Limited
Website
https://phasescientific.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Phase Scientific is a Hong Kong-headquartered diagnostics company (UCLA spin-out, founded 2015) that has commercialized PHASIFY™, a proprietary urine concentration technology enabling non-invasive biomarker-based testing for cancer screening, women's health, and infectious disease detection across 30+ countries.
Ownership category
akta.pro rank

Phase Scientific industry classification

Industry
Product category
In Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAHAAAG
Urinalysis & Routine Screening Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories

Keywords

  • Urine diagnostics
  • Liquid biopsy tests
  • Rapid antigen tests
  • Cervical cancer screening
  • Point-of-care diagnostics

Where Phase Scientific is headquartered

Location

Headquarters

HQ city
Hong Kong
HQ country
Hong Kong SAR China
HQ region
Asia

Offices3 records

Markets served

Phase Scientific business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others

Revenue model

  1. Diagnostic Test Products: Sale of over 30 innovative diagnostic products across respiratory, gastrointestinal, women's health, sexual health, pediatric health, and oncology. Over 100 million test products delivered globally to date.
  2. Laboratory Testing Services: Over 8 million laboratory tests conducted, generating revenue from laboratory service fees.
  3. Distribution Agreement Revenue: Revenue from distribution agreements including milestone pre-payments and product order payments. Total pre-payments from Phase Scientific to Lumos Diagnostics reached US$7.5 million under the FebriDx distribution agreement.
  4. FebriDx US Distribution: Commercial deployment of FebriDx point-of-care test across US healthcare settings following FDA CLIA waiver, with reimbursement secured at $41.38 per test from CMS.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goFebriDx test reimbursement

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Phase Scientific product offering

Product offering

Core offering

Phase Scientific develops and commercializes proprietary urine-based diagnostic tests built on its PHASIFY™ urine concentration technology platform, which captures biomarker detection sensitivity over 10x the industry gold standard. The company sells a portfolio of 30+ diagnostic products — including the INDICAID® rapid antigen tests, PhaseLab™ HPV Urine Detection for cervical cancer screening, and the FDA-cleared FebriDx® point-of-care respiratory infection test — and provides clinical laboratory testing services through its PhaseLab and Onco Medical Laboratory subsidiaries.

Product overview

Phase Scientific is a biotechnology company that has developed PHASIFY™ as its core proprietary urine concentration technology platform, which captures biomarker detection sensitivity over 10x the industry gold standard. The company offers a portfolio of diagnostic products including INDICAID rapid tests, PhaseLab™ HPV urine detection for cervical cancer screening, and FebriDx® for point-of-care respiratory infection differentiation. The PHASIFY technology platform serves as the foundation enabling multiple product lines spanning cancer early screening, women's health, and infectious disease diagnostics, all based on non-invasive urine sample collection.

Differentiator

Problem solved

Functional benefit

Products and services

  • PHASIFY™ Proprietary urine concentration technology platform that captures biomarker detection sensitivity at over 10 times the industry gold standard, enabling non-invasive early disease detection through liquid biopsy diagnostics. Forms the foundational IP underlying the company's diagnostic products.
  • INDICAID® (妥析) Brand name under which Phase Scientific offers point-of-care diagnostic products including rapid antigen tests, distributed across multiple countries for infectious disease detection.
  • PhaseLab™ HPV Urine Detection Next-generation urine-based HPV DNA detection system for cervical cancer screening; in clinical studies demonstrated over 97% concordance with standard physician-collected samples for HPV 16/18 detection and 93.4% sensitivity for CIN2+ lesions.
  • FebriDx® Rapid point-of-care test that differentiates bacterial from non-bacterial respiratory infections; received FDA 510(k) clearance and CLIA waiver, enabling use across over 300,000 US healthcare settings including urgent care centers and retail health clinics.
  • PhaseLab (相达医学) Laboratory testing services brand offering clinical diagnostic testing services using Phase Scientific's proprietary technologies; over 8 million laboratory tests conducted to date.
  • Onco Medical Laboratory (安球医学化验所) Oncology-focused medical laboratory providing diagnostic testing services related to cancer screening and detection.

Quantifiable outcome

  • 93.4% sensitivity for CIN2+ lesions in cervical cancer screening using urine HPV testing
  • +2 more outcomes

Companies that use Phase Scientific

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Phase Scientific technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Phase Scientific partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • Shenzhen Media Public Welfare FoundationminorGTM or Marketing Partner · 5 March 2026Charitable partnership for cervical cancer screening公益 program targeting 17,000 women in Guang'an region. Donation directed through 'Shenxin Public Welfare Fund' for grassroots female health screening initiatives using Phase Scientific's urine HPV testing technology.
  • Lumos Diagnostics Holdings LtdcoreChannel Partner/ Reseller/ DistributorExclusive US distribution partnership for FebriDx point-of-care test with a $317 million, 6-year distribution agreement. Phase Scientific received milestone pre-payments totaling $7.5 million following FDA CLIA waiver, with commercial infrastructure built out for broad deployment.
  • Beijing University Shenzhen HospitalcoreStrategic or Co-development PartnerClinical research partner for urine HPV cervical cancer screening studies involving 17,000 women. Published clinical validation data showing 93.4% sensitivity for CIN2+ lesions and over 97% consistency with standard testing. Partner for SCOCCAPS study on cervical cancer prevention innovation model.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

Phase Scientific competitors and assessment

Company assessment

Emerging players

  • GRAIL: Multi-cancer early detection company developing Galleri blood-based screening test. Represents the strategic archetype Phase Scientific aims to compete with using urine-based PHASIFY technology, though GRAIL is much further along in clinical validation and commercialization.
  • Exact Sciences: Commercial-stage cancer screening company behind Cologuard (CRC) and Oncotype DX. Represents the gold standard business model for non-invasive cancer screening that Phase Scientific's PHASIFY-based liquid biopsy aspirations aim to replicate in urine.

Broad incumbents

  • Roche Diagnostics: Global diagnostics incumbent whose Cobas 4800 HPV test is the gold standard that PhaseLab HPV Urine Detection demonstrated 97% concordance with. Operates broadly across IVD, molecular diagnostics, and women's health with significantly larger scale and clinical evidence base.
  • Abbott Diagnostics: Global diagnostics incumbent where Phase Scientific's CSO previously served 18 years. Competes across rapid diagnostics, core laboratory, molecular, and point-of-care testing. Phase Scientific's positioning as a urine-based diagnostics innovator is partly built against Abbott's installed testing infrastructure.

Direct peers

  • Cepheid (Danaher): Market leader in molecular point-of-care testing with GeneXpert systems deployed across US urgent care and hospital settings. Competes with FebriDx in respiratory infection differentiation and represents the dominant POCT benchmark Phase Scientific must displace at Certificate of Waiver facilities.
  • Hologic: Leading women's health diagnostics company with the Aptima HPV testing franchise that competes directly with PhaseLab's urine-based HPV detection. Also operates in molecular diagnostics, cervical cancer screening, and infectious disease rapid testing — overlapping multiple Phase Scientific verticals.
  • Lumos Diagnostics: Developer of FebriDx — the rapid point-of-care bacterial vs viral infection test for which Phase Scientific holds exclusive US distribution rights under a $317M, 6-year agreement. Direct product/partner overlap makes Lumos both commercial partner and closest functional peer.
  • QuidelOrtho: Specialized rapid diagnostics company with Sofia and Triage product lines for respiratory and infectious disease testing. Competes with both FebriDx in point-of-care respiratory infection differentiation and INDICAID rapid antigen tests, with similar US CLIA-waived distribution channels.

Regional players

  • Sansure Biotech: China-based molecular diagnostics company where Phase Scientific's new CSO previously served as CTO. Competes in IVD reagents, infectious disease molecular testing, and cancer diagnostics across Greater China — the most direct regional comparison given overlapping leadership pedigree and product overlap.
  • Burning Rock Biotech: China-based oncology diagnostics company specializing in next-generation sequencing for cancer therapy selection and minimal residual disease (MRD) testing. Directly comparable to Onco Medical Laboratory in targeting Chinese oncology diagnostics market with molecular approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Phase Scientific social profiles

Digital presence

Phase Scientific financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phase Scientific leadership team

Management profile

Number of profiles

Profiles12 records

Phase Scientific subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Phase Scientific funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phase Scientific M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phase Scientific

What does Phase Scientific do?

Phase Scientific develops and commercializes proprietary urine-based diagnostic tests built on its PHASIFY™ urine concentration technology platform, which captures biomarker detection sensitivity over 10x the industry gold standard. The company sells a portfolio of 30+ diagnostic products — including the INDICAID® rapid antigen tests, PhaseLab™ HPV Urine Detection for cervical cancer screening, and the FDA-cleared FebriDx® point-of-care respiratory infection test — and provides clinical laboratory testing services through its PhaseLab and Onco Medical Laboratory subsidiaries.

Is Phase Scientific a public or private company?

Phase Scientific is a private company. It is classified as venture growth investor backed and is currently operating.

When was Phase Scientific founded?

Phase Scientific was founded in 2015. It employs 51 to 100 people.

Where is Phase Scientific based?

Phase Scientific is headquartered in Hong Kong, Hong Kong SAR China, in the Asia region.

How does Phase Scientific make money?

Four revenue lines are on record. Diagnostic Test Products are the primary driver. The others are laboratory Testing Services, distribution Agreement Revenue and febriDx US Distribution.

Who are Phase Scientific's main competitors?

Emerging players on record are GRAIL and Exact Sciences. Broad incumbents are Roche Diagnostics and Abbott Diagnostics. Direct peers are Cepheid (Danaher), Hologic, Lumos Diagnostics and QuidelOrtho. Regional players are Sansure Biotech and Burning Rock Biotech.

Does Phase Scientific have an API?

No public API is recorded for Phase Scientific.

What industry is Phase Scientific in?

Phase Scientific's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAG, Urinalysis & Routine Screening Diagnostics, with a secondary code of HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
South China Morning PostSpirit of Hong Kong Awards: biotech firm eyes cervical cancer test breakthroughHong Kong biotech founder Ricky Chiu is advancing urine-based HPV testing for cervical cancer screening, using sample-concentration technology from his company Phase Scientific. The firm, known for its pandemic rapid antigen test Indicaid, now seeks to apply that experience to longer-term research.The AustralianLumos Diagnostics lands PHASE Scientific orderLumos Diagnostics has received a purchase order worth US$767,800 from PHASE Scientific for its FebriDx test, which distinguishes between bacterial and viral respiratory infections. This order is part of a six-year distribution agreement and follows a CLIA waiver granted by the US FDA in March 2026. The delivery of the product is expected to continue through October 2026 as Lumos advances its commercialization efforts.YahooLumos Diagnostics enters US commercial growth phase targeting a billion dollar opportunityLumos Diagnostics has entered the US commercial growth phase for its FebriDx test after securing a CLIA waiver, which allows the product to be used at over 300,000 healthcare locations. The company has established an exclusive distribution partnership with PHASE Scientific and received initial funding and purchase orders to support this expansion into the outpatient market.ProactiveinvestorsLumos Diagnostics secures US$768,000 FebriDx order as US commercial rollout gathers paceLumos Diagnostics has received a US$767,800 purchase order for its FebriDx rapid diagnostic test from US distribution partner PHASE Scientific, marking the first order linked to the US$5 million prepayment the company received following FDA CLIA waiver in March 2026. The order will be fulfilled progressively through October 2026, coinciding with the upcoming US influenza season when demand for rapid respiratory infection testing typically increases. Lumos CEO Doug Ward expressed encouragement about the commercial momentum as the company works to expand FebriDx adoption across US healthcare settings.AInvestLumos Diagnostics - receives US$767,800 FebriDx order from Phase ScientificLumos Diagnostics has received a US$767,800 purchase order for its FebriDx® rapid diagnostic test from PHASE Scientific, its exclusive U.S. distribution partner. The order is part of a broader six-year commercial agreement with a total contract value of up to US$317 million and supports PHASE Scientific's efforts to scale FebriDx® commercialization across the U.S. market. The test, which has FDA 510(k) clearance, is currently undergoing a CLIA waiver study expected to complete by August 2026, which would expand the product's addressable market to physician offices and urgent care clinics.YahooLumos secures US$5m FebriDx milestone payment as US rollout gains tractionLumos Diagnostics Holdings Ltd has received a US$5 million milestone pre-payment from its US distribution partner Phase Scientific, following FDA 510(k) clearance and CLIA waiver for the FebriDx point-of-care test. The CLIA waiver expands the addressable market to over 300,000 healthcare settings across the US, including urgent care centres and retail health clinics. The payment is a pre-payment for future product orders rather than immediate revenue, bringing total pre-payments from Phase Scientific to US$7.5 million.Clinical Lab ProductsFDA Grants CLIA Waiver for Rapid Test That Differentiates Bacterial and Non-Bacterial Respiratory InfectionsThe FDA granted a CLIA waiver for FebriDx, a rapid point-of-care test that differentiates bacterial from non-bacterial respiratory infections, enabling its use across any Certificate of Waiver facility in the US. The waiver expands potential access to over 300,000 US locations, reaching an estimated 80 million patients annually who present with acute respiratory infections. PHASE Scientific, the exclusive US distributor under a distribution agreement with Lumos Diagnostics, announced the waiver on March 27 and indicated its commercial infrastructure is largely built out for broad deployment.openPR.comCompetitive Analysis: Leading Companies and New Entrants in the Cervical Intraepithelial Neoplasia MarketThe Business Research Company published a market analysis projecting the cervical intraepithelial neoplasia (CIN) market to reach $1.66 billion by 2030, growing at a compound annual growth rate of 8.0%, driven by advances in early detection, biomarker-guided treatments, and AI-assisted diagnostic technologies. Notable developments highlighted include a January 2024 partnership between Becton, Dickinson and Company and Techcyte Inc. to launch an AI-driven digital cervical cytology system, and a September 2025 urine-based HPV screening study by PHASE Scientific International Limited involving 17,000 women. The report also lists approximately 22 pharmaceutical, diagnostic, and biotechnology companies operating in this market space.YicaiglobalPhase Scientific Bags USD34 Million in Asia’s Largest Diagnostics Series A Fundraiser Since 2019Phase Scientific raised USD34 million in Series A financing, led by a Value Partners Group fund. The Hong Kong-based diagnostics firm will use the funds to accelerate R&D and commercialization, including its urine-based HPV test, which showed 93.4% sensitivity in a clinical study. The test is expected to launch within a year.PR NewswirePHASE Scientific Launches World's Largest Urine-Based Cervical Cancer (HPV) Screening Clinical Study, Marking New Era of Non-Invasive Cervical Cancer ScreeningPHASE Scientific International Limited announced the launch of the world's largest clinical study for urine-based cervical cancer (HPV) screening in Guang'an, Sichuan Province, China, with 17,000 eligible women enrolled and led by Peking University Shenzhen Hospital. The study uses PHASE Scientific's proprietary PHASiFY™ technology, which concentrates trace HPV DNA in urine by more than 10,000 times, achieving 93.42% sensitivity for high-risk HPV detection and over 97% concordance with clinician-collected vaginal swabs. The research sets three world records including the largest global clinical study on urine-based HPV subtyping and the first prospective study on urine-based genetic methylation testing for cervical cancer screening, aiming to address China's current screening coverage gap of 51.5% among women aged 35–64 against the WHO's 70% benchmark.